Cargando…

The Role of NcRNAs to Regulate Immune Checkpoints in Cancer

At present, the incidence of cancer is becoming more and more common, but its treatment has always been a problem. Although a small number of cancers can be treated, the recurrence rates are generally high and cannot be completely cured. At present, conventional cancer therapies mainly include chemo...

Descripción completa

Detalles Bibliográficos
Autores principales: Jiang, Yicun, Zhao, Leilei, Wu, Yiwen, Deng, Sijun, Cao, Pu, Lei, Xiaoyong, Yang, Xiaoyan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9019622/
https://www.ncbi.nlm.nih.gov/pubmed/35464451
http://dx.doi.org/10.3389/fimmu.2022.853480
_version_ 1784689329420894208
author Jiang, Yicun
Zhao, Leilei
Wu, Yiwen
Deng, Sijun
Cao, Pu
Lei, Xiaoyong
Yang, Xiaoyan
author_facet Jiang, Yicun
Zhao, Leilei
Wu, Yiwen
Deng, Sijun
Cao, Pu
Lei, Xiaoyong
Yang, Xiaoyan
author_sort Jiang, Yicun
collection PubMed
description At present, the incidence of cancer is becoming more and more common, but its treatment has always been a problem. Although a small number of cancers can be treated, the recurrence rates are generally high and cannot be completely cured. At present, conventional cancer therapies mainly include chemotherapy and radiotherapy, which are the first-line therapies for most cancer patients, but there are palliatives. Approaches to cancer treatment are not as fast as cancer development. The current cancer treatments have not been effective in stopping the development of cancer, and cancer treatment needs to be imported into new strategies. Non-coding RNAs (ncRNAs) is a hot research topic at present. NcRNAs, which include microRNAs (miRNAs), circular RNAs (circRNAs), and long non-coding RNAs (lncRNAs), participate in all aspects of cancer biology. They are involved in the progression of tumors into a new form, including B-cell lymphoma, glioma, or the parenchymal tumors such as gastric cancer and colon cancer, among others. NcRNAs target various immune checkpoints to affect tumor proliferation, differentiation, and development. This might represent a new strategy for cancer treatment.
format Online
Article
Text
id pubmed-9019622
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-90196222022-04-21 The Role of NcRNAs to Regulate Immune Checkpoints in Cancer Jiang, Yicun Zhao, Leilei Wu, Yiwen Deng, Sijun Cao, Pu Lei, Xiaoyong Yang, Xiaoyan Front Immunol Immunology At present, the incidence of cancer is becoming more and more common, but its treatment has always been a problem. Although a small number of cancers can be treated, the recurrence rates are generally high and cannot be completely cured. At present, conventional cancer therapies mainly include chemotherapy and radiotherapy, which are the first-line therapies for most cancer patients, but there are palliatives. Approaches to cancer treatment are not as fast as cancer development. The current cancer treatments have not been effective in stopping the development of cancer, and cancer treatment needs to be imported into new strategies. Non-coding RNAs (ncRNAs) is a hot research topic at present. NcRNAs, which include microRNAs (miRNAs), circular RNAs (circRNAs), and long non-coding RNAs (lncRNAs), participate in all aspects of cancer biology. They are involved in the progression of tumors into a new form, including B-cell lymphoma, glioma, or the parenchymal tumors such as gastric cancer and colon cancer, among others. NcRNAs target various immune checkpoints to affect tumor proliferation, differentiation, and development. This might represent a new strategy for cancer treatment. Frontiers Media S.A. 2022-04-06 /pmc/articles/PMC9019622/ /pubmed/35464451 http://dx.doi.org/10.3389/fimmu.2022.853480 Text en Copyright © 2022 Jiang, Zhao, Wu, Deng, Cao, Lei and Yang https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Jiang, Yicun
Zhao, Leilei
Wu, Yiwen
Deng, Sijun
Cao, Pu
Lei, Xiaoyong
Yang, Xiaoyan
The Role of NcRNAs to Regulate Immune Checkpoints in Cancer
title The Role of NcRNAs to Regulate Immune Checkpoints in Cancer
title_full The Role of NcRNAs to Regulate Immune Checkpoints in Cancer
title_fullStr The Role of NcRNAs to Regulate Immune Checkpoints in Cancer
title_full_unstemmed The Role of NcRNAs to Regulate Immune Checkpoints in Cancer
title_short The Role of NcRNAs to Regulate Immune Checkpoints in Cancer
title_sort role of ncrnas to regulate immune checkpoints in cancer
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9019622/
https://www.ncbi.nlm.nih.gov/pubmed/35464451
http://dx.doi.org/10.3389/fimmu.2022.853480
work_keys_str_mv AT jiangyicun theroleofncrnastoregulateimmunecheckpointsincancer
AT zhaoleilei theroleofncrnastoregulateimmunecheckpointsincancer
AT wuyiwen theroleofncrnastoregulateimmunecheckpointsincancer
AT dengsijun theroleofncrnastoregulateimmunecheckpointsincancer
AT caopu theroleofncrnastoregulateimmunecheckpointsincancer
AT leixiaoyong theroleofncrnastoregulateimmunecheckpointsincancer
AT yangxiaoyan theroleofncrnastoregulateimmunecheckpointsincancer
AT jiangyicun roleofncrnastoregulateimmunecheckpointsincancer
AT zhaoleilei roleofncrnastoregulateimmunecheckpointsincancer
AT wuyiwen roleofncrnastoregulateimmunecheckpointsincancer
AT dengsijun roleofncrnastoregulateimmunecheckpointsincancer
AT caopu roleofncrnastoregulateimmunecheckpointsincancer
AT leixiaoyong roleofncrnastoregulateimmunecheckpointsincancer
AT yangxiaoyan roleofncrnastoregulateimmunecheckpointsincancer